Late 2025 and early 2026 have marked a pivotal moment in healthcare and pharma. From the U.S. FDA’s removal of suicide warnings from GLP-1 drug labels to higher-dose and oral approvals for semaglutide, alongside India’s entry into affordable tirzepatide, recent developments reflect growing confidence in metabolic therapies. Together with the first new motion-sickness drug in decades, these milestones signal a shift toward safer, more effective, and more accessible treatments that prioritize both outcomes and quality of life.
Suicide Warning Dropped for GLP-1 Drugs
January 13, 2026
The U.S. FDA has requested that marketing authorization holders remove references to suicidal thoughts and behaviors from the labeling of GLP-1 receptor agonist medications that currently carry such language. The request applies to products including Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide).
The FDA conducted a comprehensive meta-analysis of clinical trial data to better characterize the potential psychiatric risk associated with GLP-1 receptor agonists. The analysis compared the incidence of suicidal ideation and behavior in patients treated with GLP-1 receptor agonists versus placebo.
It included 91 placebo-controlled trials involving 107,910 participants, of whom 60,338 received a GLP-1 receptor agonist, and 47,572 received a placebo. The findings showed no increased risk of suicidal thoughts or behaviors with GLP-1 receptor agonist treatment compared with placebo, nor an elevated risk of other psychiatric adverse events.
Higher-Dose Semaglutide (Wegovy) Wins Approval in UK
January 12, 2026
Novo Nordisk’s semaglutide (Wegovy ®) received a new approval from the MHRA for a 7.2 mg once-weekly maintenance dose for weight management in adults with obesity.
The approval is based on results from the STEP UP trial, which evaluated a higher maintenance dose of semaglutide in patients who did not achieve sufficient weight loss on the standard 2.4 mg regimen.
Patients receiving semaglutide 7.2 mg achieved a mean weight loss of 18.7%, compared with 3.9% in the placebo group. The higher dose also outperformed the approved 2.4 mg dose, delivering mean bodyweight reductions of 18.7% versus 15.6%. Around one-third of adults with obesity achieved at least 25% weight loss after 72 weeks on the 7.2 mg dose. Overall, the higher-dose regimen demonstrated superior efficacy over both placebo and the 2.4 mg dose, while maintaining a favourable risk–benefit profile.
Novo Nordisk has applied for approval of a single-injection formulation delivering the full dose at once, which is expected to become available later this year.
Motion Sickness Drug Approved in Decades: Tradipitant (NEREUS)
December 30, 2025
Rounding out December’s landmark announcements, the FDA approved Tradipitant, marketed as NEREUS™, for the prevention of motion-induced vomiting in adults. Developed by Vanda Pharmaceuticals, this approval marks the first new pharmacologic option for motion sickness in over 40 years. Tradipitant is an oral neurokinin-1 (NK-1) receptor antagonist, targeting central vomiting pathways.
The FDA’s decision was based on two Phase 3 trials:
- Motion Syros (n=365): Vomiting incidence of ~18–19% with tradipitant versus ~44% with placebo
- Motion Serifos (n=316): Vomiting rates of ~10–18% with tradipitant versus ~38% with placebo
The recommended dose is 85 mg or 170 mg, taken as a single dose approximately 60 minutes before the event likely to cause vomiting. Common adverse effects reported include somnolence, headache, and fatigue.
This approval highlights renewed interest in quality-of-life therapies—areas long underserved due to limited commercial focus, despite significant patient burden.
Weight-Loss Breakthrough: Oral Semaglutide (WEGOVY) Approved
December 22, 2025
The U.S. FDA approved oral semaglutide (Wegovy®) for chronic weight management—making it the first and only oral GLP-1 therapy approved for obesity.
Developed by Novo Nordisk, the once-daily pill is indicated for adults with obesity, to be used alongside a reduced-calorie diet and increased physical activity. The company has announced plans to introduce the therapy in the U.S. in early January 2026.
Approval was supported by robust clinical evidence from the OASIS and SELECT trial programs. In the OASIS 4 study, patients receiving once-daily oral semaglutide achieved a mean weight loss of 13.6% at 64 weeks, significantly outperforming placebo when combined with lifestyle counselling.
The Wegovy® pill will be available in doses of 1.5 mg, 4 mg, 9 mg, and 25 mg, with treatment initiated at 1.5 mg and escalated every 30 days as tolerated until the target dose is reached.
Beyond efficacy, this approval is notable for what it represents: a potential shift in patient acceptance and adherence. Oral delivery eliminates injection fatigue, lowers psychological barriers, and may significantly expand the population willing to initiate GLP-1 therapy.
Cipla Launches Yurpeak, Its Tirzepatide Bet for Obesity & Diabetes
December 10, 2025
Cipla announced the launch of Yurpeak®, its branded version of tirzepatide, for the management of obesity and type 2 diabetes in India. This marks the second tirzepatide brand in the Indian market, following the innovator product. In a market where affordability and long-term adherence remain key barriers, local manufacturing and competition could meaningfully expand access to advanced incretin therapies.
Tirzepatide’s dual GIP and GLP-1 receptor agonist has already demonstrated superior metabolic benefits compared with traditional GLP-1 therapies, positioning it as a powerful option for patients with obesity and diabetes—conditions that continue to rise sharply in India.
Yurpeak® is available as a once-weekly injectable delivered via the KwikPen® device, offering six dosage strengths—2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. This wide titration range allows clinicians to individualize therapy while improving tolerability and long-term adherence.
Being priced on par with Mounjaro means Yurpeak’s monthly treatment cost is expected to range broadly, depending on dose, with lower doses starting at roughly ₹14,000 per month and higher doses up to ~₹27,500 per month, similar to Mounjaro’s pricing in the Indian market.
Further Reading
- https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
- Wharton S, Freitas P, Hjelmesæth J, Kabisch M, Kandler K, Lingvay I, Quiroga M, Rosenstock J, Garvey WT; STEP UP trial group. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025 Nov;13(11):949-963.https://pubmed.ncbi.nlm.nih.gov/40961952/
- https://www.msn.com/en-xl/news/other/triple-strength-wegovy-mega-dose-given-green-light-by-nhs-watchdog/ar-AA1U6S2
- https://www2.assets.vandapharma.com/Nereus/Prescribing_Information_NDA_220152_Nereus.pdf
- https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-approval-of-nereus-tradipitant-for-the-prevention-of-vomiting-induced-by-motion-a-historic-scientific-milestone-in-the-prevention-of-motion-sickness-302650965.html
- https://www.wegovy.com/obesity/starting-wegovy/starting-wegovy-pill.html#once-daily-dosing-plan
- https://www.cipla.com/press-releases-statements/cipla-launches-yurpeakr-tirzepatide-treatment-obesity-and-type-2-diabetes
